Notably, the magnitude of decreased TILs seemed to be numerically larger in HER2-positive breast cancer implying a potential synergistic interaction between HER2-targeted therapy and chemotherapy regarding pattern of TIL changes over time. Here, ERBB2 is linked to breast carcinoma.